Login / Signup

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.

Elaine M WalshAyca GucalpSujata PatilMarcia EdelweissDara S RossPedram RazaviShanu ModiNeil M IyengarRachel SanfordTiffany Troso-SandovalMila GorskyJacqueline BrombergPamela DrullinskyDiana LakeSerena WongPatricia Ann DeFuscoNicholas LamparellaRanja GuptaTasmila TabassumLeigh Ann BoyleArtavazd ArumovTiffany A Traina
Published in: Breast cancer research and treatment (2022)
This clinical trial demonstrates that adjuvant enzalutamide is a feasible and well-tolerated regimen in patients with an early-stage AR + TNBC. Randomized trials in the metastatic setting may inform patient selection through biomarker development; longer follow-up is needed to determine the effect of anti-androgens on DFS and OS in this patient population.
Keyphrases
  • early stage
  • prostate cancer
  • clinical trial
  • sentinel lymph node
  • case report
  • squamous cell carcinoma
  • small cell lung cancer
  • phase ii
  • randomized controlled trial
  • study protocol
  • open label
  • lymph node
  • rectal cancer